Abstract:Synthetic short interfering RNA (siRNA) oligonucleotides can trigger the RNA interference pathway and lead to selective gene silencing. Despite considerable enthusiasm and investment, formidable challenges remain that may deter translating this breakthrough discovery into clinical applications. In particular, the development of efficient, nontoxic, nonimmunogenic methods for delivering siRNA in vivo has proven to be exceptionally challenging. Thorough analysis of the relationship between the structure and function of siRNA carrier systems, both in isolation and in complex with RNA, will facilitate the design of efficient nonviral siRNA delivery vehicles. In this study, we explore the relationship between the physicochemical characteristics and the biological activity of "lipitoid" compounds as potent siRNA delivery vehicles. Lipitoids are cationic peptidomimetic oligomers incorporating a peptoid and a phospholipid moiety. Lipitoids can associate with siRNA oligonucleotides and self-assemble into spherical lipitoid-based nanoparticles (LNPs), with dimensions that are dependent upon the medium and the stoichiometric ratio between the cationic monomers of the lipitoid and anionic siRNA oligonucleotides. The morphology, gene silencing efficiency, and cytotoxicity of the siRNA-loaded LNPs are similarly sensitive to the stoichiometry of the complexes. The medium in which the LNPs are formed affects the assembled cargo particles' characteristics such as particle size, transfection efficiency, and stability. Formation of the LNPs in the biological, serum-free medium OptiMEM resulted in LNPs an order of magnitude larger than LNPs formed in water, and were twice as efficient in siRNA transfection compared to LNPs formed in water. Inhibitor studies were conducted to elucidate the efficiency of lysosomal escape and the uptake mechanism of the siRNA-loaded LNPs. Our results suggest that these lipitoid-based, siRNA-loaded spherical LNPs are internalized through a lipid raft-dependent and dynamin-mediated pathway, circumventing endosomal and lysosomal encapsulation. The lipitoid-siRNA nanospheres proved to be suitable platforms for investigating the critical parameters determining the efficiency of transfection agents, revealing the necessity for conducting characterization studies in biological media. The investigation of the LNP internalization pathway points to an alternative uptake route that bypasses the lysosome, explaining the surprisingly high efficiency of LNPs and suggesting that the uptake mechanism should be probed rather than assumed for the next generation of rationally designed transfection agents.

Lipid‐based nanotherapeutics for siRNA delivery

Development of lipidoid–siRNA formulations for systemic delivery to the liver

Lipid-Based Nanoparticles in the Systemic Delivery of Sirna

In Vivo Delivery of RNAi with Lipid-Based Nanoparticles.

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

Lipid Nanoparticles for Hepatic Delivery of Small Interfering Rna

Lipids and Lipid Derivatives for RNA Delivery

Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity

A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes

Liquid crystalline inverted lipid phases encapsulating siRNA enhance lipid nanoparticle mediated transfection

Lipid-based siRNA Nanodelivery Systems: A Learning Process for Improving Transfer from Concepts to Clinical Applications

Chemical Modification and Delivery System of Small Interfering RNA Drugs

Lipid-based nanoparticle formulations for small molecules and RNA drugs

Enhancing siRNA delivery by employing lipid nanoparticles

Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA

Chemical modulation of siRNA lipophilicity for efficient delivery

Synthetic SiRNA Delivery: Progress and Prospects

Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity

Novel Lipoidal Amine-Based Nanocarrier Formulations for Sirna Delivery

Non-viral vectors for the mediation of RNAi.

Delivery materials for siRNA therapeutics